การวิเคราะห์อภิมานประสิทธิศักย์ของ Lorcaserin ในการลดขนาดร่างกาย ความดันโลหิต ระดับไขมัน และระดับน้ำตาลสะสมในเลือด
Article Sidebar
Published:
Apr 23, 2018
Keywords:
lorcaserin anthropological parameter blood pressure lipid profile blood glucose
Main Article Content
Abstract
This study aimed to assess lorcaserin efficacy for improving anthropological parameters, blood pressure, lipid profile and blood glucose. The databases included PubMed, ScienceDirect and Cochrane Library from inception to July 2017. For this analysis, we selected randomized controlled trial conducted in human dosed with various doses of larcaserin. We performed a quality assessment of the retrieved studied using Jadad’s scoring and Cochrane’s risk of bias assessment. Seven studies (8,606 participants) met inclusion criteria. The dose of lorcasrine was 10-20 mg/day orally used varying from 4 weeks to 2 years. Meta-analysis revealed a reduction in BMI (weight mean difference; WMD -0.73 kg/m2; 95 % CI -0.89, -0.58), body weight (WMD -1.67 kg; 95 % CI -2.16, -1.19), waist circumference (WMD -1.72 cm; 95 % CI -2.19, -1.25) and hip circumference (WMD -0.91 cm; 95 % CI -1.67, -0.14). Similar results were observed for LDL-cholesterol (WMD -2.64 mg/dL; 95 % CI -4.34, -0.94), TC (WMD -3.48 mg/dL; 95 % CI -4.56, -2.41) and TG (WMD -4.11 mg/dL; 95 % CI -6.51, -1.72). Moreover, participants administrated lorcaserin significant reduction in HbA1C (WMD -0.25 %; 95 % CI -0.50, -0.01), fasting insulin (WMD -1.39 uIU/mL; 95 % CI -2.07, -0.72) and HOMA-IR (WMD -0.25; 95 % CI -0.30, -0.20). No serious adverse effects were found in either the lorcaserin or comparator groups. In conclusion, lorcaserin improved anthropological parameters, lipid profile, HbA1C, serum insulin and HOMA-IR.
Keywords: lorcaserin; anthropological parameter; blood pressure; lipid profile; blood glucose
Article Details
Section
Medical Sciences
References
[1] Garvey, W.T., Mechanick, J.I. and Brett, E.M., 2016, American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity, AACE/ACE obesity CPG, Endocr. Pract. 22: 1-203
[2] Eckel, R.H., Grundy, S.M. and Zimmet, P.Z., 2005, The metabolic syndrome, Lancet 365: 1415-1428.
[3] Kumanyika, S.K., Obarzanek, E. and Stettler, N., 2008, Populationbased prevention of obesity – The need for comprehensive promotion of healthful eating, physical activity, and energy balance – A scientific statement from American heart association council on epidemiology and prevention, inter-disciplinary committee for prevention (formerly the expert panel on population and prevention science), Circulation 118: 428-464.
[4] Eckel, R.H, Jakicic, J.M. and Ard, J.D., 2014, 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk, Circulation 129: S76-S99.
[5] U.S. Food and Drug Administration, BELVIQ (lorcaserin hydrochloride) tablets, 2012, Available Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022529s003lbl.pdf, June 17, 2017.
[6] Chan, E.W., He, Y., Chui, C.S., Wong, A.Y., Lau, W.C. and Wong, I.C., 2013, Efficacy and safety of lorcaserin in obese adults: A meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs, Obes. Rev. 14: 383-392.
[7] Moher, D., Liberati, A. and Tetzlaff, J, 2009, The PRISMA Group (2009) preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, PLoS. Med. 6: e1000097.
[8] Jadad, A.R., Moore, R.A., Carroll, D. and Jenkison, C., 1996, Assessing the quality of randomize controlled trials: IS blinding necessary, Elsevier Science, Inc., 17: 1-12.
[9] Smith, S.R., Prosser, W.A. and Donahue, D.J., 2008, lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women, Obesity 17: 494-503.
[10] Smith, S.R., Weissman, N.J. and Anderson, C.M., 2010, Multicenter, placebo-controlled trial of lorcaserin for weight management, N. Engl. J. Med. 363: 245-256.
[11] Fidler, M.C., Sanchez, M. and Raether, B., 2011, A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial, J. Clin. Endocrinol. Metab. 96: 3067-3077.
[12] Martin, C.K., Redman, L.M. and Zhang, J., 2011, lorcaserin, a 5-HT2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure, J. Clin. Endocrinol. Metab. 96: 837-845.
[13] O’Neil, P.M., Smith, S.R. and Weissman, N.J., 2012, Randomized placebocontrolled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study, Obesity 20: 1426-1436.
[14] Farr, O.M., Upadhyay, J. and Gavrieli, A., 2016, Lorcaserin administration decreases activation of brain centers in response to food cues and these emotion- and salience-related changes correlate with weight loss effects: A 4-week-long randomized, placebo-controlled, double-blind clinical trial, Diabetes 65: 2943-2953.
[15] Smith, S.R., Garvey, W.T. and Greenway, F.L., 2017, Coadministration of lorcaserin and phentermine for weight manage-ment: A 12-week, randomized, pilot safety study, Obesity 25: 857-865.
[16] Khera, R., Murad, M.H. and Chandar, A.K., 2016, Association of pharmacological treatments for obesity with weight loss and adverse events a systematic review and meta-analysis, JAMA 315: 2424-2434.
[17] Neff, L.M., Broder, M.S. and Beenhouwer, D., 2017, Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity, Clin. Obes. 2017: doi: 10.1111/cob.12213
[18] Lam, D.D., Przydzial, M.J. and Ridley, S.H., 2008, Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors, Endocrinology 149: 1323-1328.
[19] Heisler, L.K., Jobst, E.E. and Sutton, G.M., 2006, Serotonin reciprocally regulates melanocortin neurons to modulate food intake, Neuron 51: 239-249.
[20] Nguyen, C.T., Zhou, S. and Shanahan, W., 2016, Lorcaserin in obese and overweight patients taking prohibited serotonergic agents: A retrospective analysis, Clin. Ther. 38: 1498-509.
[21] Nuffer, W., Trujillo, J.M. and Megyeri, J., 2016, A comparison of new pharmaco-logical agents for the treatment of obesity, Ann. Pharmacother. 50: 376-388.
[22] Taylor, J.R., Dietrich, E. and Powell, J., 2013, Lorcaserin for weight management, Diabetes Metab. Syndr. Obes. 6: 209-216.
[23] Harvey, J.A., 2003, Role of the serotonin 5-HT(2A) receptor in learning, Learn. Mem. 10: 355-362.
[24] Barnes, N.M. and Sharp, T., 1999, A review of central 5-HT receptors and their func-tion, Neuropharmacology 38: 1083-1152.
[25] Meltzer, H.Y., 1999, The role of serotonin in antipsychotic drug action, Neuro-psychopharmacology 21: S106-S115.
[26] Rothman, R.B., Baumann, M.H. and Savage, J.E., 2000, Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications, Circulation 102: 2836-2841.
[27] Fitzgerald, L.W., Burn, T.C. and Brown, B.S., 2000, Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine, Mol. Pharmacol. 57: 75-81.
[28] Sachdev, M., Miller, W.C., Ryan, T. and Jollis, J.G., 2002, Effect of fenfluramine-derivative diet pills on cardiac valves: A meta-analysis of observational studies, Am. Heart. J. 144: 1065-1073.
[29] Weissman, N.J., Panza, J.A., Tighe, J.F. and Gwynne, J.T., 2001, Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy: A randomized, double-blind, placebo-controlled trial, Ann. Int. Med. 134: 267-273.
[30] Hofmann, C., Penner, U. and Dorow, R., 2006, Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis, Clin. Neuropharmacol. 29: 80-86.
[31] Thomsen, W.J., Grottick, A.J. and Menzaghi, F., 2008, Lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist: In vitro and in vivo pharmaco-logical characterization, J. Pharmacol. Exp. Ther. 325: 577-587.
[32] Smith, B.M., Smith, J.M. and Tsai, J.H., 2008, Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity, J. Med. Chem. 51: 305-313.
[33] Gustafson, A., King, C. and Rey, J.A., 2013, lorcaserin (Belviq): A selective serotonin 5-HT2C agonist in the treatment of obesity, P. T. 38: 525-534.
[34] American Diabetes Association, 2017, Obesity management for the treatment of type 2 diabetes, Sec. 7: In standards of medical care in diabetes 2017, Diabetes Care 40: S57-S63.
[35] Daneschvar, H.L., Aronson, M.D. and Smetana G.W., 2016, FDA-approved anti-obesity drugs in the United States, Am. J. Med. 129: 879.e1-6.
[36] Chuemongkon, W. and , Kruetiwa, N., 2014, Lorcaserin: A novel selective 5-HT2c receptor agonist for weight reduction, Thai Pharm. Health Sci. J. 9: 34-38.
[2] Eckel, R.H., Grundy, S.M. and Zimmet, P.Z., 2005, The metabolic syndrome, Lancet 365: 1415-1428.
[3] Kumanyika, S.K., Obarzanek, E. and Stettler, N., 2008, Populationbased prevention of obesity – The need for comprehensive promotion of healthful eating, physical activity, and energy balance – A scientific statement from American heart association council on epidemiology and prevention, inter-disciplinary committee for prevention (formerly the expert panel on population and prevention science), Circulation 118: 428-464.
[4] Eckel, R.H, Jakicic, J.M. and Ard, J.D., 2014, 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk, Circulation 129: S76-S99.
[5] U.S. Food and Drug Administration, BELVIQ (lorcaserin hydrochloride) tablets, 2012, Available Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022529s003lbl.pdf, June 17, 2017.
[6] Chan, E.W., He, Y., Chui, C.S., Wong, A.Y., Lau, W.C. and Wong, I.C., 2013, Efficacy and safety of lorcaserin in obese adults: A meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs, Obes. Rev. 14: 383-392.
[7] Moher, D., Liberati, A. and Tetzlaff, J, 2009, The PRISMA Group (2009) preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, PLoS. Med. 6: e1000097.
[8] Jadad, A.R., Moore, R.A., Carroll, D. and Jenkison, C., 1996, Assessing the quality of randomize controlled trials: IS blinding necessary, Elsevier Science, Inc., 17: 1-12.
[9] Smith, S.R., Prosser, W.A. and Donahue, D.J., 2008, lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women, Obesity 17: 494-503.
[10] Smith, S.R., Weissman, N.J. and Anderson, C.M., 2010, Multicenter, placebo-controlled trial of lorcaserin for weight management, N. Engl. J. Med. 363: 245-256.
[11] Fidler, M.C., Sanchez, M. and Raether, B., 2011, A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial, J. Clin. Endocrinol. Metab. 96: 3067-3077.
[12] Martin, C.K., Redman, L.M. and Zhang, J., 2011, lorcaserin, a 5-HT2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure, J. Clin. Endocrinol. Metab. 96: 837-845.
[13] O’Neil, P.M., Smith, S.R. and Weissman, N.J., 2012, Randomized placebocontrolled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study, Obesity 20: 1426-1436.
[14] Farr, O.M., Upadhyay, J. and Gavrieli, A., 2016, Lorcaserin administration decreases activation of brain centers in response to food cues and these emotion- and salience-related changes correlate with weight loss effects: A 4-week-long randomized, placebo-controlled, double-blind clinical trial, Diabetes 65: 2943-2953.
[15] Smith, S.R., Garvey, W.T. and Greenway, F.L., 2017, Coadministration of lorcaserin and phentermine for weight manage-ment: A 12-week, randomized, pilot safety study, Obesity 25: 857-865.
[16] Khera, R., Murad, M.H. and Chandar, A.K., 2016, Association of pharmacological treatments for obesity with weight loss and adverse events a systematic review and meta-analysis, JAMA 315: 2424-2434.
[17] Neff, L.M., Broder, M.S. and Beenhouwer, D., 2017, Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity, Clin. Obes. 2017: doi: 10.1111/cob.12213
[18] Lam, D.D., Przydzial, M.J. and Ridley, S.H., 2008, Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors, Endocrinology 149: 1323-1328.
[19] Heisler, L.K., Jobst, E.E. and Sutton, G.M., 2006, Serotonin reciprocally regulates melanocortin neurons to modulate food intake, Neuron 51: 239-249.
[20] Nguyen, C.T., Zhou, S. and Shanahan, W., 2016, Lorcaserin in obese and overweight patients taking prohibited serotonergic agents: A retrospective analysis, Clin. Ther. 38: 1498-509.
[21] Nuffer, W., Trujillo, J.M. and Megyeri, J., 2016, A comparison of new pharmaco-logical agents for the treatment of obesity, Ann. Pharmacother. 50: 376-388.
[22] Taylor, J.R., Dietrich, E. and Powell, J., 2013, Lorcaserin for weight management, Diabetes Metab. Syndr. Obes. 6: 209-216.
[23] Harvey, J.A., 2003, Role of the serotonin 5-HT(2A) receptor in learning, Learn. Mem. 10: 355-362.
[24] Barnes, N.M. and Sharp, T., 1999, A review of central 5-HT receptors and their func-tion, Neuropharmacology 38: 1083-1152.
[25] Meltzer, H.Y., 1999, The role of serotonin in antipsychotic drug action, Neuro-psychopharmacology 21: S106-S115.
[26] Rothman, R.B., Baumann, M.H. and Savage, J.E., 2000, Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications, Circulation 102: 2836-2841.
[27] Fitzgerald, L.W., Burn, T.C. and Brown, B.S., 2000, Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine, Mol. Pharmacol. 57: 75-81.
[28] Sachdev, M., Miller, W.C., Ryan, T. and Jollis, J.G., 2002, Effect of fenfluramine-derivative diet pills on cardiac valves: A meta-analysis of observational studies, Am. Heart. J. 144: 1065-1073.
[29] Weissman, N.J., Panza, J.A., Tighe, J.F. and Gwynne, J.T., 2001, Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy: A randomized, double-blind, placebo-controlled trial, Ann. Int. Med. 134: 267-273.
[30] Hofmann, C., Penner, U. and Dorow, R., 2006, Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis, Clin. Neuropharmacol. 29: 80-86.
[31] Thomsen, W.J., Grottick, A.J. and Menzaghi, F., 2008, Lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist: In vitro and in vivo pharmaco-logical characterization, J. Pharmacol. Exp. Ther. 325: 577-587.
[32] Smith, B.M., Smith, J.M. and Tsai, J.H., 2008, Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity, J. Med. Chem. 51: 305-313.
[33] Gustafson, A., King, C. and Rey, J.A., 2013, lorcaserin (Belviq): A selective serotonin 5-HT2C agonist in the treatment of obesity, P. T. 38: 525-534.
[34] American Diabetes Association, 2017, Obesity management for the treatment of type 2 diabetes, Sec. 7: In standards of medical care in diabetes 2017, Diabetes Care 40: S57-S63.
[35] Daneschvar, H.L., Aronson, M.D. and Smetana G.W., 2016, FDA-approved anti-obesity drugs in the United States, Am. J. Med. 129: 879.e1-6.
[36] Chuemongkon, W. and , Kruetiwa, N., 2014, Lorcaserin: A novel selective 5-HT2c receptor agonist for weight reduction, Thai Pharm. Health Sci. J. 9: 34-38.